Findings

The quality of primary care management of diabetes is lower for physicians with higher-volume practices, but higher for those with greater diabetes-specific volume, reports a study in Annals of Internal Medicine.

Risk of end stage renal disease (ESRD) shows more than twofold variation across different racial/ethnic groups, according to a paper in the American Journal of Kidney Diseases.

Patterns of end stage renal disease (ESRD) among live kidney donors may differ for those with ESRD developing earlier versus later in the postdonation period, suggests a study in the American Journal of Transplantation.

Data on kidney function and microalbuminuria are associated with the risk of congestive heart failure in an African American population, reports a study in Nephrology Dialysis Transplantation.

/kidneynews/9_1/15b/graphic/15bf1.jpg

Among patients with moderate to severe chronic kidney disease, several measures of metabolic health are better in those with higher physical activity, reports a study in BMC Nephrology.

Compared to cyclosporine, belatacept-based immunosuppression improves long-term outcomes in extended criteria donor (ECD) kidney recipients, reports a study in the American Journal of Transplantation.

Patients with acute kidney injury (AKI) seen in the emergency department are at increased risk of chronic kidney disease (CKD) and death within 5 years, reports a study in Kidney International.

Five years after the shift to a “bundled” reimbursement system and revised drug labeling for erythrocyte-stimulating agents (ESAs), overall outcomes are no worse—and some outcomes have improved—for hemodialysis patients covered by fee-for-service Medicare, reports a study in JAMA Internal Medicine.

Available evidence shows no consistent benefit of percutaneous angioplasty with stent replacement over medical therapy for patients with atherosclerotic renal artery stenosis (ARAS), concludes an updated systematic review in the Annals of Internal Medicine.

Adjuvant treatment with the oral antiangiogenic drug sunitinib increases disease-free survival but increases toxicity in patients with metastatic renal cell carcinoma (RCC) at high risk of recurrence, reports a trial in The New England Journal of Medicine.

Pages